Form 4: Monopar Therapeutics' Chief Operating Officer Increases Stake in Company

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, has recently acquired a total of 36,000 shares of common stock through a series of transactions.

Summary

• Andrew Cittadine, the Chief Operating Officer of Monopar Therapeutics, has reported changes in beneficial ownership of the company's stock.
• Over three days, from May 29 to May 31, 2024, Cittadine purchased a total of 36,000 shares of Monopar Therapeutics' common stock.
• On May 29, 2024, he acquired 12,000 shares at a weighted average price of $0.6369.
• On May 30, 2024, he acquired another 12,000 shares at a weighted average price of $0.6397.
• On May 31, 2024, he acquired a further 12,000 shares at a weighted average price of $0.6443.
• Following these transactions, Cittadine directly owns 93,624 shares of Monopar Therapeutics' common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the scale of the purchases is not significant enough to warrant a strong positive sentiment.

Positives

• The COO's increased investment could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that a company insider believes the company's stock is undervalued or that the company's prospects are strong.

Stakeholder Impact

• Shareholders may view the COO's stock purchases as a positive signal.

Key Dates